TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$460 Million


Follow-on Offering

Bookrunner, October 2020


Ultragenyx is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare diseases. Founded in 2010, Ultragenyx has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are typically no approved therapies treating the underlying disease. The Company’s strategy, which is predicated upon time- and cost-efficient drug development, enables the Company to pursue multiple programs in parallel with the goal of delivering safe and effective therapies to patients with the utmost urgency.